Inspire Pharmaceuticals, Inc.
4222 Emperor Boulevard
Suite 200
Durham,
NC 27703
United States - Map
Phone: 919-941-9777
Fax: 919-941-9797
Web Site: http://www.inspirepharm.com
| Inspire Pharmaceuticals, Inc., a biopharmaceutical company, engages in researching, developing, and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. The company offers AzaSite, an azithromycin ophthalmic solution and topical anti-infective; Elestat, an epinastine HCl ophthalmic solution and topical antihistamine for the prevention of ocular itching associated with allergic conjunctivitis; and Restasis, a cyclosporine ophthalmic emulsion for the treatment of dry eye disease in adults and children in the United States. Its product candidates in clinical development include Prolacria, a diquafosol tetrasodium for the treatment of dry eye disease in phase III; denufosol tetrasodium, an inhaled product for the treatment of cystic fibrosis in phase III; AzaSite for the treatment of blepharitis, which is in phase II; and INS115644 and INS117548, which are in phase I clinical trial for the treatment of glaucoma or ocular hypertension. The company has a joint license agreement with Allergan, Inc. to develop and commercialize Prolacria; a license agreement with InSite Vision Incorporated to commercialize AzaSite, as well as other topical anti-infective products containing azithromycin used in the treatment of human ocular or ophthalmic indications primarily in the U.S. and Canada; and a development, license, and supply agreement with Santen Pharmaceutical Co., Ltd. for the development of diquafosol tetrasodium for the therapeutic treatment of ocular surface diseases in Asia. Inspire Pharmaceuticals was founded in 1993 and is based in Durham, North Carolina. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Christy Shaffer Ph.D., 51
Chief Exec. Officer, Pres, Director and Member of Devel. Committee |
$
651.00K |
$
0 | Mr. Thomas R. Staab II, CPA., 41
Chief Financial Officer, Principal Accounting Officer, Exec. VP and Treasurer |
$
394.00K |
$
0 | Mr. Joseph K. Schachle , 44
Chief of Commercial & Corp. Operations and Exec. VP |
$
406.00K |
$
0 | Dr. Benjamin R. Yerxa Ph.D., 43
Chief Scientific Officer, Chief of R&D and Exec. VP |
$
424.00K |
$
106.00K | Mr. Joseph M. Spagnardi , 46
Sr. VP, Sec. and Gen. Counsel |
$
365.00K |
$
0 |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.51% Nasdaq 
0.06 (1.01%) 
Profile
